Nonreplicating Recombinant Vaccinia Virus Expressing CD40 Ligand Enhances APC Capacity to Stimulate Specific CD4+ and CD8+ T Cell Responses
Authors:
- 1 March 2005
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 16 (3) , 348-360
Abstract
Recombinant poxviruses expressing immunomodulatory molecules together with specific antigens represent powerful vaccines for cancer immunotherapy. Recently, we and others have demonstrated, in vitro and in vivo, that coexpression of CD80 and CD86 costimulatory molecules enhances the immunogenic capacity of a recombinant vaccinia virus (rVV) encoding different tumor-associated antigens. To further investigate the capacity of these vectors to provide ligands for different costimulatory pathways relevant in the generation of T cell responses, we constructed a recombinant virus (rVV) expressing CD40 ligand or CD154 (CD154rVV). Upon binding the CD40 receptor expressed on antigen presenting cells (APC), this molecule, physiologically expressed on activated CD4+ T cells, increases their antigen presentation and immunostimulatory capacities. Therefore, we evaluated the effects of CD154rVV infection on APC activation and its consequences on T cell stimulation. CD154rVV infection of autologous fibroblasts, monocytes, or iDC promoted the expression of a number of cytokines, including GM-CSF, TNF-α, and IL-15 in iDC. Most importantly, IL-12 p40 gene expression and protein secretion were induced by CD154rVV but not by wild-type VV (WT VV) in either CD14+ cells or iDC, and these effects could be blocked by anti-CD40 monoclonal antibodies. Furthermore, phenotypic characterization of CD154rVV infected iDC revealed enhanced expression of CD83 and CD86 surface markers as compared with wild-type vaccinia virus infection. As expected, VV infection triggered cytokines gene expression in cultures including APC and T cells from VV immune donors. However, cytokine genes typically expressed by T cell receptor triggered T cells such as those encoding IL-2 and IFN-γ, or T cell proliferation, were detectable to a significantly higher extent in CD154rVV infected cultures, as compared with WT VV. Activation of specific CD8+ T cells was then investigated using MART-1/Melan-A27–35 epitope as the model of tumor-associated antigen (TAA). In the presence of CD154rVV activated APCs, significantly higher numbers of specific cytotoxic CD8+ T cells were detected, as compared with cultures performed in the presence of WT VV or in the absence of virus. Taken together, these data indicate that functional CD154 expression from rVV infected cells promotes APC activation, thereby enhancing antigen-specific T cell generation. Such a recombinant vector might help bypass the requirement for activated helper cells during CTL priming, thus qualifying as a potentially relevant vector in the generation of CD8+ T cell responses in cancer immunotherapy.Keywords
This publication has 54 references indexed in Scilit:
- Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T CellsJournal of Experimental Medicine, 2003
- Myocardial tumor necrosis factor–α expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device supportThe Annals of Thoracic Surgery, 2001
- Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2000
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- Activated T cells induce interleukin‐12 production by monocytes via CD40‐CD40 ligand interactionEuropean Journal of Immunology, 1995
- Human CD40‐ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE productionFEBS Letters, 1993
- Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.Journal of Experimental Medicine, 1992
- Molecular and biological characterization of a murine ligand for CD40Nature, 1992
- Structure of vaccinia virus early promotersJournal of Molecular Biology, 1989
- A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDSNature, 1988